Michael Wheatcroft
Directeur Technique/Scientifique/R&D chez TELIX PHARMACEUTICALS LIMITED
Postes actifs de Michael Wheatcroft
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Michael Wheatcroft
Anciens postes connus de Michael Wheatcroft
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Medimmune UK Ltd.
 Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Corporate Officer/Principal | - | - |
Avipep Pty Ltd.
 Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Corporate Officer/Principal | - | - |
Formation de Michael Wheatcroft
| University of Cambridge | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 3 |
| Australie | 3 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
| Process Industries | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TELIX PHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
Medimmune UK Ltd.
Medimmune UK Ltd. Chemicals: Major DiversifiedProcess Industries Medimmune UK Ltd. manufactures chemical products. The company was founded on October 6, 1999 and is headquartered in Speke, the United Kingdom. | Process Industries |
Avipep Pty Ltd.
Avipep Pty Ltd. Medical SpecialtiesHealth Technology Avipep Pty Ltd. commercializes protein biopharmaceuticals and in-vivo diagnostic products. It focuses on developing Avibodies as a platform for targeting cells in the body with a focus on antibody-drug conjugates (ADC) for the treatment of cancer. The company was founded on April 7, 2005 and is headquartered in Parkville, Australia. | Health Technology |
- Bourse
- Insiders
- Michael Wheatcroft
- Expérience
